Evidence map›Paper›PMID 29079777›Full record

ArticleScientific reports2017

Pharmacological preconditioning with gemfibrozil preserves cardiac function after heart transplantation.

Kálmán Benke, Csaba Mátyás, Alex Ali Sayour, Attila Oláh, Balázs Tamás Németh, Mihály Ruppert, Gábor Szabó, Gábor Kökény, Eszter Mária Horváth, István Hartyánszky and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 2 countries.

Kálmán BenkeHeart and Vascular Center, Semmelweis University, Budapest, Hungary. kalman.benke@gmail.com.
Csaba MátyásHeart and Vascular Center, Semmelweis University, Budapest, Hungary.
Alex Ali SayourHeart and Vascular Center, Semmelweis University, Budapest, Hungary.
Attila OláhHeart and Vascular Center, Semmelweis University, Budapest, Hungary.
Balázs Tamás NémethHeart and Vascular Center, Semmelweis University, Budapest, Hungary.ORCID 0000-0001-7202-8107
Mihály RuppertHeart and Vascular Center, Semmelweis University, Budapest, Hungary.
Gábor SzabóDepartment of Cardiac Surgery, University of Heidelberg, Heidelberg, Germany.
Gábor KökényDepartment of Pathophysiology, Semmelweis University, Budapest, Hungary.
Eszter Mária HorváthDepartment of Physiology, Semmelweis University, Budapest, Hungary.
István HartyánszkyHeart and Vascular Center, Semmelweis University, Budapest, Hungary.
Zoltán SzabolcsHeart and Vascular Center, Semmelweis University, Budapest, Hungary.
Béla MerkelyHeart and Vascular Center, Semmelweis University, Budapest, Hungary.
Tamás RadovitsHeart and Vascular Center, Semmelweis University, Budapest, Hungary.
Semmelweis University · HUHeidelberg University · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

While heart transplantation (HTX) is the definitive therapy of heart failure, donor shortage is emerging. Pharmacological activation of soluble guanylate cyclase (sGC) and increased cGMP-signalling have been reported to have cardioprotective properties. Gemfibrozil has recently been shown to exert sGC activating effects in vitro. We aimed to investigate whether pharmacological preconditioning of donor hearts with gemfibrozil could protect against ischemia/reperfusion injury and preserve myocardial function in a heterotopic rat HTX model. Donor Lewis rats received p.o. gemfibrozil (150 mg/kg body weight) or vehicle for 2 days. The hearts were explanted, stored for 1 h in cold preservation solution, and heterotopically transplanted. 1 h after starting reperfusion, left ventricular (LV) pressure-volume relations and coronary blood flow (CBF) were assessed to evaluate early post-transplant graft function. After 1 h reperfusion, LV contractility, active relaxation and CBF were significantly (p < 0.05) improved in the gemfibrozil pretreated hearts compared to that of controls. Additionally, gemfibrozil treatment reduced nitro-oxidative stress and apoptosis, and improved cGMP-signalling in HTX. Pharmacological preconditioning with gemfibrozil reduces ischemia/reperfusion injury and preserves graft function in a rat HTX model, which could be the consequence of enhanced myocardial cGMP-signalling. Gemfibrozil might represent a useful tool for cardioprotection in the clinical setting of HTX surgery soon.

Indexed as

Heart TransplantationIschemic Preconditioning, MyocardialAnimalsCoronary VesselsCyclic GMPGemfibrozilGene Expression RegulationHeartHemodynamicsLeukocytesMaleMyocardiumNitric Oxide Synthase Type IIIPlatelet ActivationRatsRNA, MessengerCyclic GMPGemfibrozilNitric Oxide Synthase Type IIIRNA, Messenger

Identifiers

PMID29079777
PMCPMC5660179
OpenAlexW2765615380

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.